Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Department of Health Care, Jinling Hospital, Medical School of Nanjing University.
Medicine (Baltimore). 2023 Aug 4;102(31):e33797. doi: 10.1097/MD.0000000000033797.
In the last few years, treatment of head and neck squamous cell carcinoma (HNSCC) has been enhanced by the emergence of immunotherapy. A biological phenomenon unique to immunotherapy is pseudoprogression, an increase in tumor burden or the appearance of a new lesion subsequently followed by tumor regression.
A 78-year-old man complaining of a lump (6*4 cm) gradually swelling on the right side of his neck with recurrent buccal mucosa squamous cell carcinoma presented to our institution. Two months prior, he received resection of the buccal lesion but refused suggested adjuvant chemoradiotherapy after the operation.
Recurrent buccal mucosa squamous cell carcinoma.
Induction immunotherapy was initiated, followed by a new node appearing on the surface of the neck mass. We considered the presence of pseudoprogression and continued with immunotherapy. The patient received immunotherapy combined with chemotherapy and intensity-modulated radiation therapy (IMRT) consecutively.
The patient experienced an excellent recovery with the disappearance of pain and the lump, along with return of a healthy appetite, weight gain and positive outlook. Complete response (CR) was also noted by magnetic resonance imaging (MRI) scan, with the upper right neck mass significantly retreated to unclear display. The patient is still alive with stable, asymptomatic disease at the time of this writing.
These results provide confidence in the safety and efficacy of radical chemo-radio-immunotherapy for the treatment of recurrent, unresectable or metastatic HNSCC.
在过去的几年中,免疫疗法的出现增强了头颈部鳞状细胞癌(HNSCC)的治疗效果。免疫疗法的一个独特的生物学现象是假性进展,即肿瘤负荷增加或新病变出现,随后肿瘤消退。
一名 78 岁男性,因右侧颈部肿块(6*4cm)逐渐增大并伴有复发性颊黏膜鳞状细胞癌来我院就诊。两个月前,他接受了颊部病变切除术,但术后拒绝了建议的辅助放化疗。
复发性颊黏膜鳞状细胞癌。
开始诱导免疫治疗,随后颈部肿块表面出现新的淋巴结。我们考虑存在假性进展,并继续进行免疫治疗。患者接受了免疫治疗联合化疗和调强放疗(IMRT)。
患者疼痛和肿块消失,食欲恢复,体重增加,精神状态良好,恢复良好。磁共振成像(MRI)扫描显示完全缓解(CR),右上颈部肿块明显退缩,显示不清。截至本文撰写时,患者仍存活且无症状。
这些结果为根治性放化疗免疫治疗复发性、不可切除或转移性 HNSCC 提供了安全性和有效性的信心。